These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38767403)

  • 1. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management.
    Ramirez-Gamero A; Martínez-Cordero H; Beltrán BE; Florindez J; Malpica L; Castillo JJ
    Am J Hematol; 2024 Aug; 99(8):1586-1594. PubMed ID: 38767403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
    Castillo JJ; Reagan JL; Sikov WM; Winer ES
    Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
    Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
    Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
    Dittus C; Grover N; Ellsworth S; Tan X; Park SI
    Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
    Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
    Kobayashi H; Miyagi N
    Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
    Beltran BE; Castro D; Paredes S; Miranda RN; Castillo JJ
    Am J Hematol; 2020 Apr; 95(4):435-445. PubMed ID: 32072672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
    Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
    Arora N; Gupta A; Sadeghi N
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
    Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
    Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report.
    Yu M; Zhang Q; Xu S; Yin T; Li F
    Anticancer Drugs; 2022 Jan; 33(1):e769-e775. PubMed ID: 34387604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
    Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
    Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
    Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
    Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
    Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
    [No Abstract]   [Full Text] [Related]  

  • 17. CD56-positive diffuse large B-cell lymphoma/leukemia with
    Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
    J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
    Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
    Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
    Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.